Pro Medicus (OTCMKTS:PMCUF) Sees Large Volume Increase – Here’s What Happened

Shares of Pro Medicus Limited (OTCMKTS:PMCUF – Get Free Report) saw an uptick in trading volume on Wednesday. Approximately 3,195 shares were traded during trading, an increase of 464% from the previous session’s volume of 566 shares. The stock last traded at $124.40 and had previously closed at $115.0991.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group lowered shares of Pro Medicus from a “buy” rating to a “hold” rating in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $155.00.

View Our Latest Stock Report on Pro Medicus

Pro Medicus Price Performance

The business has a 50-day simple moving average of $120.36 and a two-hundred day simple moving average of $113.79.

Pro Medicus Company Profile

(Get Free Report)

Pro Medicus Limited is an Australian medical technology company that develops software for medical imaging and healthcare organizations. Its solutions are designed to help hospitals, radiology practices and other providers store, manage, view and distribute medical images and related clinical information.

The company’s principal platform is Visage 7, an enterprise imaging system developed and commercialized through its wholly owned subsidiary, Visage Imaging. The platform supports the review of diagnostic studies such as computed tomography, magnetic resonance imaging and other medical images, with an emphasis on enterprise-wide access, workflow efficiency and advanced visualization.

Founded in 1983 and headquartered in Melbourne, Australia, Pro Medicus serves healthcare customers in Australia, North America and Europe.

Featured Stories

Receive News & Ratings for Pro Medicus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro Medicus and related companies with MarketBeat.com's FREE daily email newsletter.